Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study

被引:27
|
作者
Clarkesmith, Danielle E. [1 ]
Lip, Gregory Y. H. [1 ,2 ]
Lane, Deirdre A. [1 ,2 ]
机构
[1] Univ Birmingham, Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Inst Cardiovasc Sci, Dudley Rd, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Patient education; Dabigatran; Warfarin; Anticoagulation; NET CLINICAL BENEFIT; STROKE PREVENTION; DECISION AID; OF-LIFE; ANTITHROMBOTIC THERAPY; MODELING ANALYSIS; DABIGATRAN; ADHERENCE; WARFARIN; POPULATION;
D O I
10.1016/j.thromres.2017.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Qualitative research on atrial fibrillation (AF) patient's experiences and perceptions of taking the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention is limited. This study explores patients' experiences of dabigatran and their recommendations for development of educational materials. Patients and methods: Semi-structured individual interviews with 8 warfarin-naive and 8 warfarin-experienced AF patients, using qualitative deductive thematic analysis. Results: The four main overarching themes included: understanding the diagnosis; reaching a treatment decision; challenges of living with OAC; and patient perceptions of treatment. Patients discussed their shock of diagnosis, and seeking information and support at that time. Narratives suggest patients preferred to be led by the doctor when making treatment decisions, and would often compare dabigatran to warfarin. Patients reported side-effects and challenges with both treatment options, and discussed their beliefs surrounding medications, including misconceptions. In addition to the original framework, two further themes were added: challenges of living with AF, and patient recommendations. Generally patients found AF symptoms distressing, which impacted their quality of life. Patient recommendations included the content and delivery of educational materials and development of tools to help with their understanding of AF and anticoagulation, as well as treatment adherence and anxiety surrounding symptoms and side effects. Conclusion: Patient recommendations emphasised the need for interventions to relieve anxiety surrounding the diagnosis and possible treatment side effects. Tailored 'disease-specific' support is essential to ensure efficacious treatment. This qualitative study highlights the need for patient involvement in the development of educational materials and resources for patients commencing treatment with NOACs. Crown Copyright (C) 2017 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 50 条
  • [41] Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
    Gabitova, Mariia A.
    Krupenin, Pavel M.
    Sokolova, Anastasiya A.
    Napalkov, Dmitry A.
    Fomin, Victor V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2019, 15 (06) : 802 - 805
  • [42] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Prior Gastrointestinal Bleeding
    Kwon, Soonil
    Lee, So-Ryoung
    Choi, Eue-Keun
    Lee, Euijae
    Jung, Jin-Hyung
    Han, Kyung-Do
    Cha, Myung-Jin
    Oh, Seil
    Lip, Gregory Y. H.
    STROKE, 2021, 52 (02) : 511 - 520
  • [43] Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease
    Li, Hsing-Jung
    Lin, Shin-Yi
    Lin, Fang-Ju
    Hung, Chi-Sheng
    Wang, Chi-Chuan
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 535 - 542
  • [44] Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly
    Ajam, Tarek
    Cumpian, Tabitha L.
    Tilkens, Blair L.
    Jahangir, Imaan A.
    Frost, Jared
    Ceretto, Cheryl
    Jahangir, Arshad
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (12) : 1309 - 1327
  • [45] Outcomes After Cardioversion in Atrial Fibrillation Patients Treated with Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Insights from a Meta-Analysis
    Sen, Parijat
    Kundu, Amartya
    Sardar, Partha
    Chatterjee, Saurav
    Nairooz, Ramez
    Amin, Hossam
    Aronow, Wilbert S.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (01) : 33 - 41
  • [46] The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation A PRISMA-compliant article
    Liu, Xuyang
    Huang, Manxiang
    Ye, Caisheng
    Zeng, Junquan
    Zeng, Changai
    Ma, Jianyong
    MEDICINE, 2020, 99 (27)
  • [47] Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Yamaji, Hirosuke
    Murakami, Takashi
    Hina, Kazuyoshi
    Higashiya, Shunichi
    Kawamura, Hiroshi
    Murakami, Masaaki
    Kamikawa, Shigeshi
    Komatsubara, Issei
    Kusachi, Shozo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 69 (02) : 118 - 126
  • [48] Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    van den Dries, Carline J.
    Pajouheshnia, Romin
    van den Ham, Hendrika A.
    Souverein, Patrick
    Moons, Karel G. M.
    Hoes, Arno W.
    Geersing, Geert-Jan
    van Doorn, Sander
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (02) : 751 - 761
  • [49] Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study
    Xing, Lucas Yixi
    Barcella, Carlo Alberto
    Sindet-Pedersen, Caroline
    Bonde, Anders Nissen
    Gislason, Gunnar Hilmar
    Olesen, Jonas Bjerring
    THROMBOSIS RESEARCH, 2019, 178 : 101 - 109
  • [50] Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory
    Blann, A. D.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) : 158 - 167